Zoetis Inc. (0M3Q.L)
USD 169.5
(-0.56%)
USD 169.5
(-0.56%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.56 Billion USD | 9.34% |
| 2022 | 2.34 Billion USD | 21.94% |
| 2021 | 1.92 Billion USD | 18.12% |
| 2020 | 1.62 Billion USD | 15.46% |
| 2019 | 1.41 Billion USD | 1.37% |
| 2018 | 1.39 Billion USD | -2.52% |
| 2017 | 1.42 Billion USD | -4.99% |
| 2016 | 1.5 Billion USD | 2.39% |
| 2015 | 1.46 Billion USD | 13.81% |
| 2014 | 1.28 Billion USD | -0.31% |
| 2013 | 1.29 Billion USD | -3.87% |
| 2012 | 1.34 Billion USD | 26.53% |
| 2011 | 1.06 Billion USD | 6.83% |
| 2010 | 995 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 2.41 Billion USD | -1.47% |
| 2024 Q2 | 2.45 Billion USD | -7.51% |
| 2024 Q1 | 2.65 Billion USD | 3.39% |
| 2023 Q4 | 2.56 Billion USD | -6.56% |
| 2023 FY | 2.56 Billion USD | 9.34% |
| 2023 Q2 | 2.7 Billion USD | 5.38% |
| 2023 Q3 | 2.74 Billion USD | 1.59% |
| 2023 Q1 | 2.56 Billion USD | 9.3% |
| 2022 Q4 | 2.34 Billion USD | 1.82% |
| 2022 FY | 2.34 Billion USD | 21.94% |
| 2022 Q2 | 2.2 Billion USD | 7.19% |
| 2022 Q1 | 2.05 Billion USD | 6.97% |
| 2022 Q3 | 2.3 Billion USD | 4.44% |
| 2021 Q2 | 1.8 Billion USD | 6.0% |
| 2021 Q3 | 1.87 Billion USD | 4.05% |
| 2021 FY | 1.92 Billion USD | 18.12% |
| 2021 Q1 | 1.7 Billion USD | 4.42% |
| 2021 Q4 | 1.92 Billion USD | 2.56% |
| 2020 Q4 | 1.62 Billion USD | 0.12% |
| 2020 FY | 1.62 Billion USD | 15.46% |
| 2020 Q1 | 1.48 Billion USD | 5.04% |
| 2020 Q2 | 1.58 Billion USD | 6.95% |
| 2020 Q3 | 1.62 Billion USD | 2.65% |
| 2019 Q4 | 1.41 Billion USD | -2.02% |
| 2019 Q1 | 1.36 Billion USD | -2.16% |
| 2019 Q2 | 1.4 Billion USD | 3.16% |
| 2019 Q3 | 1.43 Billion USD | 2.49% |
| 2019 FY | 1.41 Billion USD | 1.37% |
| 2018 Q4 | 1.39 Billion USD | -3.47% |
| 2018 FY | 1.39 Billion USD | -2.52% |
| 2018 Q3 | 1.44 Billion USD | 1.48% |
| 2018 Q2 | 1.42 Billion USD | -1.46% |
| 2018 Q1 | 1.44 Billion USD | 0.98% |
| 2017 Q3 | 1.49 Billion USD | -0.53% |
| 2017 FY | 1.42 Billion USD | -4.99% |
| 2017 Q2 | 1.49 Billion USD | -2.41% |
| 2017 Q1 | 1.53 Billion USD | 2.2% |
| 2017 Q4 | 1.42 Billion USD | -4.23% |
| 2016 FY | 1.5 Billion USD | 2.39% |
| 2016 Q1 | 1.46 Billion USD | -0.41% |
| 2016 Q3 | 1.56 Billion USD | 2.49% |
| 2016 Q2 | 1.52 Billion USD | 4.38% |
| 2016 Q4 | 1.5 Billion USD | -3.9% |
| 2015 FY | 1.46 Billion USD | 13.81% |
| 2015 Q2 | 1.41 Billion USD | 5.27% |
| 2015 Q4 | 1.46 Billion USD | 4.56% |
| 2015 Q3 | 1.4 Billion USD | -0.99% |
| 2015 Q1 | 1.34 Billion USD | 4.42% |
| 2014 Q1 | 1.31 Billion USD | 1.78% |
| 2014 Q2 | 1.33 Billion USD | 1.52% |
| 2014 Q3 | 1.38 Billion USD | 3.89% |
| 2014 Q4 | 1.28 Billion USD | -7.13% |
| 2014 FY | 1.28 Billion USD | -0.31% |
| 2013 FY | 1.29 Billion USD | -3.87% |
| 2013 Q1 | 1.12 Billion USD | -16.73% |
| 2013 Q2 | 1.25 Billion USD | 12.23% |
| 2013 Q3 | 1.29 Billion USD | 2.63% |
| 2013 Q4 | 1.29 Billion USD | 0.23% |
| 2012 Q4 | 1.34 Billion USD | 5.74% |
| 2012 Q2 | 1.17 Billion USD | -4.72% |
| 2012 Q3 | 1.27 Billion USD | 8.53% |
| 2012 FY | 1.34 Billion USD | 26.53% |
| 2012 Q1 | 1.23 Billion USD | 15.71% |
| 2011 FY | 1.06 Billion USD | 6.83% |
| 2011 Q4 | 1.06 Billion USD | 0.0% |
| 2010 FY | 995 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Editas Medicine, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 53.29 Million USD | -4711.409% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -3212.319% |
| Perrigo Company plc | 1.14 Billion USD | -124.735% |
| Illumina, Inc. | 587 Million USD | -336.797% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 49.607% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -24620.401% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 69.183% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -5988.815% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 0.639% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 516.23 Million USD | -396.672% |
| Biogen Inc. | 2.52 Billion USD | -1.448% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -23213.33% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -90789.755% |
| bluebird bio, Inc. | 22.91 Million USD | -11087.225% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -3807.167% |
| FibroGen, Inc. | 41.56 Million USD | -6068.652% |
| Agilent Technologies, Inc. | 1.03 Billion USD | -148.691% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -2776.181% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -4195.095% |
| Myriad Genetics, Inc. | 20.1 Million USD | -12656.219% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 105009.984% |
| Mettler-Toledo International Inc. | 385.86 Million USD | -564.481% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | -131.579% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | -247.049% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -8920.229% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -26316.649% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 16.1 Million USD | -15824.477% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -16840.866% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -694.155% |
| OPKO Health, Inc. | 65.69 Million USD | -3802.766% |
| Exelixis, Inc. | 17.32 Million USD | -14701.131% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -6594.517% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -33069.47% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 12.02 Million USD | -21224.019% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 21.22 Million USD | -11981.233% |
| Insmed Incorporated | 83.24 Million USD | -2979.954% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -1909.389% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -13340.973% |
| TG Therapeutics, Inc. | 39.82 Million USD | -6338.49% |
| Incyte Corporation | 62.97 Million USD | -3971.651% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -679.568% |